Research Topics
| Kalipso ChalkidouSummaryAffiliation: National Institute for Health and Clinical Excellence Country: UK Publications
| Collaborators
|
Detail Information
Publications
Evidence-based decision making: when should we wait for more information?Kalipso Chalkidou
Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA
Health Aff (Millwood) 27:1642-53. 2008..We conclude that there is a need for better integration of health care decision-making processes with research policies...- Evidence and values: paying for end-of-life drugs in the British NHSKalipso Chalkidou
NICE International, London, UK
Health Econ Policy Law 7:393-409. 2012.... - The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness researchKalipso Chalkidou
National Institute for Health and Clinical Excellence, London, UK
Clin Trials 9:436-46. 2012..While the level of interest and activity in conducting pRCTs is increasing, many challenges remain for their routine use. This article discusses those challenges and offers some potential ways forward... - Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and futureKalipso Chalkidou
NICE International, National Institute for Health and Clinical Excellence, London, UK
Pharmacoeconomics 28:799-811. 2010..We draw some possible lessons for the US, which is currently considering using CER to inform healthcare policy and practice decisions... - The (possible) impact of comparative effectiveness research on pharmaceutical industry decision makingK Chalkidou
NICE International, London, UK
Clin Pharmacol Ther 87:264-6. 2010..For health-care systems in developed and developing countries around the world, faced with limited budgets, there may be no third option... - Eliminating drug price differentials across government programmes in the USAKalipso Chalkidou
NICE International, National Institute for Health and Clinical Excellence, London, UK
Health Econ Policy Law 6:43-64. 2011.... - Pharmacogenetics and cost-effectiveness analysis: a two-way streetKalipso Chalkidou
National Institute for Health and Clinical Excellence, UK
Drug Discov Today 16:873-7. 2011.... 
Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical ExcellenceKalipso Chalkidou
National Institute for Health and Clinical Excellence
Issue Brief (Commonw Fund) 59:1-12. 2009..NICE committees consider comparative clinical and cost effectiveness, social values (including impact on equity), and U.K. and European Union legislation when making their decisions...- Comparative effectiveness research priorities: identifying critical gaps in evidence for clinical and health policy decision makingKalipso Chalkidou
National Institute of Health and Clinical Excellence, 71 High Holborn, London WC1V 6NA, UK
Int J Technol Assess Health Care 25:241-8. 2009..However, how such a function, in terms of methods and process, would go about identifying the most important priorities warranting further research has received little attention... 
Comparative effectiveness research and evidence-based health policy: experience from four countriesKalipso Chalkidou
National Institute for Health and Clinical Excellence, London, UK
Milbank Q 87:339-67. 2009..This article reviews experiences from Britain, France, Australia, and Germany...- Evidence-informed evidence-makingKalipso Chalkidou
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
J Health Serv Res Policy 13:167-73. 2008..We propose ways in which NICE can collaborate more effectively with research funders to improve the evidence base upon which it bases its recommendations... - Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of researchKalipso Chalkidou
Associate Director, Research and Development, National Institute for Health and Clinical Excellence, 71 High Holborn, WC1V 6NA, London, UK
J R Soc Med 100:453-60. 2007 - Cost-effective public health guidance: asking questions from the decision-maker's viewpointKalipso Chalkidou
Research and Development, National Institute for Health and Clinical Excellence, London, UK
Health Econ 17:441-8. 2008.... - Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary careKalipso Chalkidou
NICE International, National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London, WC1V 6NA, UK
Int J Technol Assess Health Care 27:151-8. 2011.... - Expensive cancer drugs: a comparison between the United States and the United KingdomRuth R Faden
Johns Hopkins University, Baltimore, MD 21205, USA
Milbank Q 87:789-819. 2009..This article compares the United Kingdom's and the United States' experiences with expensive cancer drugs to illustrate the challenges posed by new, extremely costly, medical technologies... - Reflections on the evolution of health technology assessment in EuropeCorinna Sorenson
Research Fellow in Health Policy, London School of Economics, London, UK
Health Econ Policy Law 7:25-45. 2012.... - Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et alSean R Tunis
Centre for Medical Technology Policy, 524 2nd Street, San Francisco, California 94107, USA
Int J Technol Assess Health Care 23:432-5. 2007 - How to formulate research recommendationsPolly Brown
BMJ Publishing Group, London WC1H 9JR
BMJ 333:804-6. 2006